Michel Velez, MD

Telephone: 
9542677700
Fax: 
9542677799
Specialty/Specialties: 
Hematology and Oncology
Holy Cross Medical Group: 
Y

Office hours
8:30 am - 4:30 pm, Mon - Fri

Focus Areas
Gastrointestinal Cancers, Hematology (benign and malignant)

Notable work experience
Affiliate Assistant Professor of Clinical Biomedical Science        
11/2015-Present
Florida Atlantic University
Department of Integrated Medical Science

Assistant Professor Florida International University                 
2/2015-Present
Herbert Wertheim College of Medicine
    
Certifications
American Board of Internal Medicine – Internal Medicine
American Board of Internal Medicine – Hematology
American Board of Internal Medicine - Oncology

Residency / Fellowship
Hematology-Oncology Chief Fellow (Post-Graduate Year 6)
7/2013- 6/2014
Jackson Memorial Hospital/University of Miami Miller School of Medicine. Miami, FL

Hematology-Oncology Fellow (Post-Graduate Year 4-5)
7/2011-6/2013
Jackson Memorial Hospital/University of Miami Miller School of Medicine. Miami, FL

Internal Medicine Residency
7/2009-6/2011
University of Miami Miller School of Medicine at JFK Medical Center and Veterans Affairs Medical Center
Regional Campus. West Palm Beach, FL

Higher Education
Universidad del Norte, Colombia                                                  
1/1994-12/2000
Degree: MD

Professional Associations
American Society of Clinical Oncology Active Member (2013)
Florida ASCO Member (2014)

Peer-Reviewed Publications and Abstracts
Luis E. Raez; Kathleen Danenberg, Aurelio B. Castrellon, Michel Velez, Joshua Usher, , Shahrooz Rabizadeh, Yolanda Jaimes, Brian Hunis, Cheryl Habaue, Peter Danenberg. Use of cell-free circulating RNA (cfRNA) levels in plasma and expression of HER2 and PD-L1 to monitor disease status in metastatic cancer patients. ASCO 2018 Annual meeting abstract submitted.

Castrellon AB, Velez M, Nguyen SM, Blaya M, Barnick S, Dumais K, LeCroy N, Raez LE. Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer. Hematol Oncol Stem Cell Ther. October 2017

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 18(10):1360-1372. October 2017

Raez LE, Danenberg K, Castrellon AB, Usher JL, Hunis B, Michel V, Habaue C, Danenberg P. Correlation of cell-free circulating DNA, RNA, and PD-L1 from plasma with clinical response in patients with metastatic lung and breast cancers. J Clin Oncol 35, 2017 (suppl; abstr 11550). Poster.
                     
Aurelio B. Castrellon, Steven B Nguyen, Adriana M Milillo, Michel Velez, Luis E Raez. Initial response to therapy with Fulvestrant and Cyclin-dependent kinase 4/6 inhibitor in a Male with stage IV breast cancer. M J Canc 2(1): 012. March 2017

Raez LE, Danenberg K, Hunis B, Castrellon A, Jaimes Y, Velez M, Usher J and    Habaue C. P2.03b-039 Cell-Free (cf) DNA and cfRNA levels in Plasma of Lung     Cancer Patients Indicate Disease Status and Predict Progression: Topic: Biomarkers. Journal of Thoracic Oncology, Vol. 12, Issue 1, S959. January 2017.

Aurelio Castrellon, Michel Velez, Marcelo Blaya, Sandra Barnick, Katerine Dumais, Nicholas LeCroy. Impact of neoaduvant weekly paclitaxel plus carboplatin followed by anthracycline/cyclophosphamide on the Residual Cancer Burden Index of patients with triple-negative breast cancer. San Antonio Breast Cancer Symposium 2016 poster session.

Lecroy N, Borrero I, Dumercy D, Velis E, Perez A, Velez M, Mani A, Castrellon A,Hwakins-Locke C, Frankel C, Sareli C, Calfa C. Impact of sequencing weekly  paclitaxel (T) and dose-dense  doxorubicin /cyclophosphamide (DDAC) on tolerability and relative dose intensity (RDI) in breast cancer (BC) patients (pts)  receiving neoadjuvant chemotherapy (NAC). Poster session ASCO annual meeting 2015.

Azzi G, Velez M, Mathias-Machado MC. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis. Curr Opin Oncol. 2014 Jul;26(4):403-7.

Moh'd Khushman,Naomi Dempsey,Jennifer Cudris Maldonado, Arturo Loaiza-Bonilla, Michel Velez, Lauren Carcas, Daniel Dammrich, Jorge Hurtado Cordovi, Ritesh Parajuli, Terri Pollack, Ana P. Harwood, Jessica Macintyre, Ching-Wei D. Tzeng, Jaime R. Merchan, Maria H. Restrepo, Ikechukwu I. Akunyili, Afonso         Ribeiro, Govindarajan Narayanan, Lorraine Portelance, Danny Sleeman, Joe U.   Levi, Caio M.S. Rocha Lima, Peter J. Hosein. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma Pancreatology Vol 15, Issue 6, December 2015, 667–673

Moh'd M. Khushman, Peter Joel Hosein, Michel Velez, et al. Updated survival analysis of patients (pts) with unresectable (UR) or borderline resectable (BR) locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX. J Clin Oncol 32, 2014 (suppl; abstr e15197).

Perez CA, Velez M, Raez LE, Santos ES. Overcoming the resistance to Crizotinib in patients with Non-Small Cell Lung Cancer harboring EML4/ALK translocation. Lung Cancer. 2014 May;8 4(2):110-115.

Belisario A. Arango1, Luis E. Aguirre1, Cesar A. Perez1, Michel Velez1, Edgardo S. Santos2, Luis E. Raez3. Targeting angiogenesis in NSCLC cancer:  A focus on current approaches and future developments. Future Medicine Jul 2013, Vol. 10, 4, 503-517.

Pimentel A, Velez M, Barahona L, Swords R, Lekakis L. New prospects for drug Development – The hedgehog pathway revealed. Focus on hematologic    malignancies. Future Oncol. 2013 May;9(5):681-97.

Velez M, Raez LE, Perez CA, Gomez JE, Mudad R, Vazquez AM, Santos ES. Abnormal elevation of erythrocyte mean corpuscular volume (MCV) in non-small cell lung cancer (NSLC) patients treated with maintenance pemtrexed-based chemotherapy. J Clin Oncol 30, 2012 (suppl; abstr e17564).

Velez M, Arango B, Raez LE, Santos ES. Mutations in tumorigenesis pathways driving personalized treatment in non-small cell lung cancer. J Clinic Experiment Pathol 2012, S5:002.

Perez CA, Arango BA, Velez M, Raez LE, Santos ES. Emergin role of multikinase inhibitors for refractory thyroid cancer. Biologics 2012; 6:257-65

Velez M, Arango BA, Perez CA, Santos ES. Safety and efficacy of pemetrexed in maintenance therapy in non-small cell lung cancer. Clin Med Insights Oncol 2012; 6:117-24

Escobar M, Velez M, Belalcazar A, Santos ES, Raez LE. The role of proteasome inhibition in non-small cell lung cancer. J Biomed Biotechnol 2011; Epub 2011 May 4

Velez M, Belalcazar A, Domingo G, Blaya M, Raez LE, Santos ES. Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. Expert Rev Anticancer Ther 2010; 10:549-547

Domingo G, Perez CA, Velez M, Cudris J, Raez LE, Santos ES. EGF receptor in lung cancer: A successful story of targeted therapy. Expert Rev Anticancer Ther 2010; 10:1577-1587

Presentations and Symposia Participation
1. Updates in the management of Triple negative breast cancer. 12th Annual New Orleans Summer Cancer Meeting. New Orleans, LA, USA. July 22nd 2017. Presenter.

2. New standard approaches in the management of breast cancer. Best of ASCO 2017 Annual Meeting, Miami, FL, USA. July 16th 2017. Presenter

3. Current perspectives in the management of breast cancer. FLASCO Business meeting. Orlando, Fl, USA. March 31st 2017. Presenter.

4. Neoadjuvant and adjuvant systemic therapies in Her2neu positive breast cancer. 14th Annual Miami Cancer Meeting. Miami, Fl, USA. Jan 2017. Presenter.

5. Immunotherapy in the management of Triple negative breast cancer. VI Congreso Internacional de Oncologia del Interior, FLASCA. Cordoba, Argentina. Nov 2016. Presenter.

6. Liquid biopsy and breast cancer. VI Congreso Internacional de Oncologia del Interior, FLASCA. Cordoba, Argentina. Nov 2016. Presenter.

7. Novel therapies in the systemic management of metastatic ER positive Her2neu negative Breast Cancer. Congreso ecancer/Liga Colombiana contra el cancer. Bogota, Colombia. Nov 2016. Presenter.

8. BRCA Mutant breast cancer and it’s implications in the Bahamian population. Bahamas Medical Association. Freeport, Bahamas. Oct 2016. Presenter.

9. Survivorship care models in Breast Cancer. Best of ASCO 2016. Miami, FL. Jul 2016. Presenter.

10. Breast cancer module session. Best of ASCO 2016. Miami, FL. Jul 2016. Session Moderator.

11. San Antonio Breast Cancer Symposium review for the Puerto Rican Hematology Oncology Association Jan 2015. Presenter


Location

4725 N. Federal Highway - Bienes Cancer Center
33308 Fort Lauderdale , FL

HCMG Practice Locations